Skip to main content
Top
Published in: Journal of Gastroenterology 2/2017

01-02-2017 | Original Article—Liver, Pancreas, and Biliary Tract

The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease

Authors: Reona Morio, Hideyuki Hyogo, Masahiro Hatooka, Kei Morio, Hiromi Kan, Tomoki Kobayashi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yoneda Masayasu, Kazuaki Chayama

Published in: Journal of Gastroenterology | Issue 2/2017

Login to get access

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is frequently associated with insulin resistance (IR) and abnormalities in glucose metabolism. Prevalent postprandial hyperinsulinemia along with insulin resistance in NAFLD may lead to hypoglycemia. This study investigated the prevalence of postprandial oxyhypoglycemia in patients with NAFLD.

Methods

The oral glucose tolerance test (OGTT) with 75 g glucose was performed in 375 biopsy-proven NAFLD patients with prior unknown type 2 diabetes mellitus (DM). Serum glucose and insulin levels were measured for 3 h after glucose loading and the clinical parameters were compared.

Results

Normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and DM were observed in 36, 36, and 28 %, respectively. Hypoglycemia (≤70 mg/dL) after 3 h was observed in 14.4 % of all patients. The rate of hypoglycemia was significantly higher in NGT (63 % of NGT) than in IGT (30 % of IGT) and DM (7 % of DM) (P < 0.05). In patients with hypoglycemia, the levels of insulin were significantly higher at 30 and 60 min than those without hypoglycemia (P < 0.05). By multivariate analysis, high-LDL cholesterolemia (P < 0.05), low-HDL cholesterolemia (P < 0.05), and fibrosis (P < 0.05) were significant factors that contributed to hypoglycemia after 3 h on 75 g OGTT.

Conclusions

A relatively higher proportion of NAFLD cases exhibited transient postprandial hypoglycemia after 3 h on OGTT, especially in NAFLD patients with early-stage fibrosis. By performing 75 g OGTT for 3 h, hypoglycemia would be diagnosed earlier and the treatment intervention would decrease the progression of NAFLD and deterioration of glucose metabolism.
Literature
1.
go back to reference Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.CrossRefPubMedPubMedCentral Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.CrossRefPubMedPubMedCentral
2.
go back to reference Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009;41(9):615–25.CrossRefPubMed Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009;41(9):615–25.CrossRefPubMed
3.
go back to reference Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9.CrossRefPubMed Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9.CrossRefPubMed
4.
go back to reference Larter CZ, Chitturi S, Heydet D, et al. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25(4):672–90.CrossRefPubMed Larter CZ, Chitturi S, Heydet D, et al. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25(4):672–90.CrossRefPubMed
5.
go back to reference Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26(Suppl 1):163–72.CrossRefPubMed Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26(Suppl 1):163–72.CrossRefPubMed
6.
go back to reference Farrel GC, Laeter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.CrossRef Farrel GC, Laeter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.CrossRef
7.
go back to reference Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRefPubMed Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRefPubMed
8.
9.
go back to reference Farrell GC. The liver and the waistline: fifty years of growth. J Gastroenterol Hepatol. 2009;24(Suppl 3):S105–18.CrossRefPubMed Farrell GC. The liver and the waistline: fifty years of growth. J Gastroenterol Hepatol. 2009;24(Suppl 3):S105–18.CrossRefPubMed
10.
go back to reference Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16.CrossRefPubMedPubMedCentral Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16.CrossRefPubMedPubMedCentral
11.
go back to reference Manchanayake J, Chitturi S, Nolan C, et al. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:510–6.CrossRefPubMed Manchanayake J, Chitturi S, Nolan C, et al. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:510–6.CrossRefPubMed
12.
go back to reference Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178–87.CrossRefPubMed Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178–87.CrossRefPubMed
13.
go back to reference Rafiq N, Bai C, Fang Y. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8.CrossRefPubMed Rafiq N, Bai C, Fang Y. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8.CrossRefPubMed
14.
go back to reference Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224–9.CrossRefPubMed Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224–9.CrossRefPubMed
15.
go back to reference Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRefPubMed
16.
go back to reference Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRefPubMed Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRefPubMed
17.
go back to reference Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8.CrossRefPubMed Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8.CrossRefPubMed
18.
go back to reference Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One. 2013;8(11):e76161.CrossRefPubMedPubMedCentral Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One. 2013;8(11):e76161.CrossRefPubMedPubMedCentral
19.
go back to reference Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–44.CrossRefPubMed Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–44.CrossRefPubMed
20.
go back to reference Megyesi C, Samols E, Marks V. Glucose tolerance and diabetesin chronic liver disease. Lancet. 1967;18:1051–6.CrossRef Megyesi C, Samols E, Marks V. Glucose tolerance and diabetesin chronic liver disease. Lancet. 1967;18:1051–6.CrossRef
21.
go back to reference Hyogo H, Yamagishi S, Maeda S, et al. Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. Dig Liver Dis. 2012;44:935–9.CrossRefPubMed Hyogo H, Yamagishi S, Maeda S, et al. Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. Dig Liver Dis. 2012;44:935–9.CrossRefPubMed
22.
go back to reference Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.CrossRefPubMedPubMedCentral Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.CrossRefPubMedPubMedCentral
23.
go back to reference Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–42.CrossRefPubMed Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–42.CrossRefPubMed
24.
go back to reference Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84.CrossRefPubMed Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84.CrossRefPubMed
25.
go back to reference Castaldo E, Sabato D, Lauro D, et al. Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One. 2011;6(12):e28312.CrossRefPubMedPubMedCentral Castaldo E, Sabato D, Lauro D, et al. Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One. 2011;6(12):e28312.CrossRefPubMedPubMedCentral
26.
27.
go back to reference Kimura Y, Hyogo H, Ishitobi T. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol. 2011;26:517–22.CrossRefPubMed Kimura Y, Hyogo H, Ishitobi T. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol. 2011;26:517–22.CrossRefPubMed
28.
go back to reference Ogata C, Ohmoto-Sekine Y, Tanabe M, et al. Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med. 2014;53(13):1401–6.CrossRefPubMed Ogata C, Ohmoto-Sekine Y, Tanabe M, et al. Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med. 2014;53(13):1401–6.CrossRefPubMed
29.
go back to reference Arya VB, Mohammed Z, Blankenstein O, et al. Hyperinsulinaemic hypoglycaemia. Horm Metab Res. 2014;46(3):157–70 (hyperinsulinaemic).CrossRefPubMed Arya VB, Mohammed Z, Blankenstein O, et al. Hyperinsulinaemic hypoglycaemia. Horm Metab Res. 2014;46(3):157–70 (hyperinsulinaemic).CrossRefPubMed
30.
go back to reference Sesti G, Hribal ML, Fiorentino TV, et al. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care. 2014;2(1):e000016.CrossRefPubMedPubMedCentral Sesti G, Hribal ML, Fiorentino TV, et al. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care. 2014;2(1):e000016.CrossRefPubMedPubMedCentral
31.
go back to reference Sugiyama S, Jinnouchi H, Hieshima K, et al. Insulin supersensitivity and normoinsulinaemic hypoglycaemia in uncontrolled type 2 diabetes mellitus: clinical usefulness of 3 h assessment in the 75 g oral glucose tolerance test. BMJ Case Rep. 2014;8:2014. Sugiyama S, Jinnouchi H, Hieshima K, et al. Insulin supersensitivity and normoinsulinaemic hypoglycaemia in uncontrolled type 2 diabetes mellitus: clinical usefulness of 3 h assessment in the 75 g oral glucose tolerance test. BMJ Case Rep. 2014;8:2014.
32.
go back to reference Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed
33.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed
34.
go back to reference Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed
35.
go back to reference Michael MD, Kulkarni RN, Postic C. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87–97.CrossRefPubMed Michael MD, Kulkarni RN, Postic C. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87–97.CrossRefPubMed
36.
go back to reference Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.CrossRefPubMed Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.CrossRefPubMed
37.
38.
go back to reference Johnson DG, Alberti KG, Faber OK, Binder C. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet. 1977;1(8001):10–3.CrossRefPubMed Johnson DG, Alberti KG, Faber OK, Binder C. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet. 1977;1(8001):10–3.CrossRefPubMed
39.
go back to reference Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12(5):1106–10.CrossRefPubMed Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12(5):1106–10.CrossRefPubMed
40.
go back to reference Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23(2):207–15.CrossRefPubMed Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23(2):207–15.CrossRefPubMed
41.
go back to reference Sonsuz A, Basaranoglu M, Bilir M, et al. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97(2):495.CrossRefPubMed Sonsuz A, Basaranoglu M, Bilir M, et al. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97(2):495.CrossRefPubMed
Metadata
Title
The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease
Authors
Reona Morio
Hideyuki Hyogo
Masahiro Hatooka
Kei Morio
Hiromi Kan
Tomoki Kobayashi
Tomokazu Kawaoka
Masataka Tsuge
Akira Hiramatsu
Michio Imamura
Yoshiiku Kawakami
Hiroshi Aikata
Hidenori Ochi
Yoneda Masayasu
Kazuaki Chayama
Publication date
01-02-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 2/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1236-7

Other articles of this Issue 2/2017

Journal of Gastroenterology 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.